Canaccord Calls Doximity, Inc. (DOCS)'s Post-Earnings Selloff an Overreaction And Sees Long-Term Upside
Doximity, Inc. (NYSE:DOCS) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts.
The stock given seventh position on our list of best healthcare stocks is Doximity, Inc. (NYSE:DOCS).
TheFly reported on February 9 that Canaccord Genuity upgraded DOCS from Hold to Buy and lowered the price target to $34 from $48. The post-earnings selloff, according to the firm, was an overreaction to immediate worries about how policy and pricing uncertainties might impact pharmaceutical budgets. It was wise to draw a line and upgrade the company, according to Canaccord, which also predicted that DOCS shares would rise sharply over the course of the upcoming year as pharmaceutical budgets level off, offering a longer-term buying opportunity.
Moreover, Doximity, Inc. (NYSE:DOCS) announced its fiscal Q3 2026 results on February 5. The company's revenue for the quarter ending December 31, 2025, was $185.1 million, a 10% rise over the previous year. While net income reached $61.6 million, suggesting a 33% margin, adjusted EBITDA climbed 9% to $111.4 million, with margins staying at 60%. According to the company, platform engagement reached all-time highs, with 720,000 active users for workflow solutions and over 300,000 people using AI features. CEO Jeff Tangney claims that platform utility has increased as a result of AI integration.
In addition, the company authorized a $500 million stock repurchase program, which underscores confidence in long-term value creation. DOCS also provided guidance for Q4 and full fiscal 2026, projecting revenues of approximately $643 million and adjusted EBITDA near $356 million.
Doximity, Inc. (NYSE:DOCS) is a U.S. digital healthcare platform connecting medical professionals with secure networking, telehealth, AI‑powered workflow tools, and clinical insights. It innovates by embedding AI, telemedicine, and productivity tools into a unified physician‑centric ecosystem that streamlines care delivery, communication, and administrative tasks.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Barclays: US-Iran conflict unlikely to end in next 12 months, oil exports near 85% of pre-war level
Jensen Huang's sudden resignation shrouded in suspicion: Did the White House secretly intervene? Is a return possible in the future?
Only a few days separated Jensen Huang’s strong support from the board last Sunday and his late-night resignation on Wednesday. Multiple reports of the Wednesday night Nvidia board meeting were co-authored by Washington-based journalists—who do not typically cover Nvidia—fueling rumors of "White House pressure and information leaks." Huang’s unique value lies in leveraging his personal reputation to secure the supply chain and drive the implementation of technological roadmaps, making him difficult to replace. Some analysts note that, drawing on examples such as Steve Jobs’ return to Apple, it is possible that Huang may come back in the future.
Gold recovers from YTD low, retakes $3,900; Fed hike bets and bullish USD to cap gains
Crypto prices
More
